Oral Insulin Enhanced by Dual-Ligand-Modified Nanoparticles via Trans-Golgi Network-Mediated Transport
ACS Nano · 2026
DOI: 10.1021/acsnano.6c13168 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Meng Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Science…. Hauptthemen laut MEDLINE: Insulin, Nanoparticles, trans-Golgi Network, Drug Carriers. Die Arbeit nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ministry of Education of the People's Republic of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Oral insulin delivery is challenged by a cascade of gastrointestinal barriers, including mucus entrapment, poor apical endocytosis, extensive lysosomal degradation, and insufficient basolateral exocytosis. To overcome these obstacles in a coordinated fashion, we engineered a dual-ligand PLGA nanoparticle (PLGA-Tf/BAC-NPs) decorated with transferrin (Tf) and the sorting peptide BAC (ADDIDLLK). Tf facilitates efficient apical endocytosis via transferrin receptor (TfR) recognition, whereas BAC not only participates in AP-2-mediated internalization but, more critically, reroutes intracellular trafficking to evade lysosomal destruction. Mechanistically, BAC sequentially recognizes GGA-1 and AP-1, directing nanoparticles from endosomes to the trans-Golgi network (TGN) and subsequently to the basolateral membrane. This synergistic ligand pairing also endows the nanoparticles with rapid mucus-penetrating capability, as corroborated by nanoparticle tracking and mucin interaction assays. In a type 1 diabetic rat model, PLGA-Tf/BAC-NPs yielded a relative oral bioavailability of 16.62% and a pharmacological bioavailability of 7.58%, sustaining euglycemia for approximately 6 h. Collectively, our findings establish a clinically relevant PLGA-based platform that integrates a “mucus penetration-cellular uptake-intracellular trafficking” strategy, substantially advancing oral insulin delivery efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Advanced Pharmaceutical Preparation, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing100191, China.
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang110016, China.
- Laboratory of Innovative Formulations and Pharmaceutical Excipients, Peking University Ningbo Institute of Marine Medicine, Ningbo315832, China.
- Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, 22 Institute of Advanced Clinical Medicine, Peking University, Beijing100191, China.
ORCID-Profile: Jian-Cheng Wang
Förderung
- National Natural Science Foundation of China
- Ministry of Education of the People's Republic of China
- Natural Science Foundation of Beijing Municipality
- Ningbo Municipal Bureau of Science and Technology
Zitieren
APA
Wang, M., Chen, Y., Li, L., Zhu, Z., Lei, L., Chen, X., Yan, Y., Liu, X., He, B., Zhu, Y., Shi, Y., & Wang, J. C. (2026). Oral Insulin Enhanced by Dual-Ligand-Modified Nanoparticles via Trans-Golgi Network-Mediated Transport. ACS Nano. https://doi.org/10.1021/acsnano.6c13168
Vancouver
Wang M, Chen Y, Li L, Zhu Z, Lei L, Chen X, et al. Oral Insulin Enhanced by Dual-Ligand-Modified Nanoparticles via Trans-Golgi Network-Mediated Transport. ACS Nano. 2026. doi:10.1021/acsnano.6c13168
BibTeX
@article{Wang2026,
author = {Wang, Meng and Chen, Yongqing and Li, Lisha and Zhu, Zehang and Lei, Lei and Chen, Xin and Yan, Yi and Liu, Xiaoyan and He, Bing and Zhu, Yuanjun and Shi, Yujie and Wang, Jian-Cheng},
title = {Oral Insulin Enhanced by Dual-Ligand-Modified Nanoparticles via Trans-Golgi Network-Mediated Transport},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c13168}
}
EUVIMED